2025

Recovering Losses on Caribou Biosciences, Inc. (NASDAQ:CRBU) Investment Introduction If you are an investor who suffered a loss on your Caribou Biosciences, Inc. (NASDAQ:CRBU) investment, you may have options to pursue a potential recovery under the federal securities laws. It is important to be informed about your rights and the steps you can take to…

Orogen Royalties Inc. Announces Grant of Share-Based Compensation Vancouver, BC / ACCESS Newswire / January 31, 2025 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. (“Orogen” or the “Company”) has recently announced the authorization of a grant of share-based compensation as part of its annual program. The Board of Directors have approved the issuance of 324,000 Restricted Share…

Recovering Losses on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investment If you find yourself facing losses from your investment in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), you may have options for potential recovery under the federal securities laws. It’s essential to understand your rights and take action if you believe you have been a victim of securities…

Sun Communities, Inc. Investment Losses Recovering Your Investment Losses If you find yourself in a situation where you have suffered a loss on your Sun Communities, Inc. (NYSE:SUI) investment, you may have options for potential recovery under the federal securities laws. It’s important to take action and understand what steps you can take to protect…

Oh No! Securities Investigation Alert! By: Your Witty Blogger Date: January 31, 2025 So, here’s the tea, folks. Levi & Korsinsky recently announced that they have started an investigation on Agilysys, Inc. for possible violations of federal securities laws. Yep, you heard it right! On January 21, 2025, Agilysys dropped a bombshell press release stating…

The Impact of Crown’s Offer on Revance Stockholders A Game-Changing Offer Revance stockholders recently received some exciting news with Crown’s offer of $3.65 per share. This offer, which was the only one available, was unanimously approved by the Revance Board of Directors. This decision has the potential to reshape the future of the company and…

Investigating Neumora Therapeutics, Inc.: A Rollercoaster of Emotions What Happened? On January 2, 2025, Neumora Therapeutics, Inc. dropped a bombshell on its investors by announcing the failure of its experimental depression treatment in the first of three planned studies. For those who had high hopes in the biotech company, this news came as a shock…